Clinical Trials
13
Active:0
Completed:13
Trial Phases
3 Phases
Phase 1:1
Phase 2:2
Phase 3:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 3
10 (76.9%)Phase 2
2 (15.4%)Phase 1
1 (7.7%)Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
Phase 3
Completed
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00200525
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
Phase 2
Completed
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00200512
- Locations
- 🇬🇧
Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
🇬🇧The Morriston Hospital, Swansea, United Kingdom
A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension
Phase 2
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT00200421
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 845
- Registration Number
- NCT00200499
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-09-20
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 825
- Registration Number
- NCT00200460
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found